Pramiconazole - Misplaced Pages

Chemical compound

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.
Find sources: "Pramiconazole" – news · newspapers · books · scholar · JSTOR (January 2021) (Learn how and when to remove this message)

Pharmaceutical compound

Pramiconazole
Clinical data

Routes of administration	By mouth
ATC code	none
Identifiers
IUPAC name 1-{4-methoxy}phenyl)piperazin-1-yl]phenyl}-3-isopropylimidazolidin-2-one
CAS Number	219923-85-0
PubChem CID	3013050 11411233
ChemSpider	2281806
UNII	4SYH0R661F
ChEMBL	ChEMBL175797
Chemical and physical data
Formula	C₃₅H₃₉F₂N₇O₄
Molar mass	659.739 g·mol
3D model (JSmol)	Interactive image
SMILES CC(C)N1CCN(C1=O)c2ccc(cc2)N3CCN(CC3)c4ccc(cc4)OC5OC(O5)(Cn6cncn6)c7ccc(cc7F)F
InChI InChI=1S/C35H39F2N7O4/c1-25(2)43-17-18-44(34(43)45)29-6-4-27(5-7-29)40-13-15-41(16-14-40)28-8-10-30(11-9-28)46-20-33-47-22-35(48-33,21-42-24-38-23-39-42)31-12-3-26(36)19-32(31)37/h3-12,19,23-25,33H,13-18,20-22H2,1-2H3/t33-,35+/m0/s1 Key:AEKNYBWUEYNWMJ-QWOOXDRHSA-N
(what is this?) (verify)

Pramiconazole is a triazole antifungal which was under development by Barrier Therapeutics for the treatment of acute skin and mucosal fungal infections but was never marketed.

References

"Pramiconazole - AdisInsight".
Geria AN, Scheinfeld NS (September 2008). "Pramiconazole, a triazole compound for the treatment of fungal infections". IDrugs: The Investigational Drugs Journal. 11 (9): 661–70. PMID 18763217.

Antifungals (D01 and J02)

Wall/
membrane

Ergosterol
inhibitors

Azoles (lanosterol 14α-
demethylase inhibitors)

Imidazoles

Systemic: ketoconazole

Triazoles

Unknown: albaconazole
ravuconazole

Thiazoles

Topical: abafungin

Polyene antimycotics
(ergosterol binding)

Topical: hamycin
natamycin
nystatin
Systemic: amphotericin B, hamycin

Squalene monooxygenase
inhibitors

Allylamines	Topical: naftifine terbinafine Systemic: terbinafine
Benzylamines	Topical: butenafine

Others

Topical: amorolfine

β-glucan synthase
inhibitors

Intracellular

Pyrimidine analogues/ thymidylate synthase inhibitors	Systemic: flucytosine
Mitotic inhibitors	Systemic: griseofulvin
Aminoacyl tRNA synthetase inhibitors	Topical: tavaborole

Others

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: